APC In the News

Tirzepatide fallout in The Hill

The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.

October 11, 2024

Echoing our position

Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.

October 10, 2024

Wired story isn’t perfect, but…

This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.

October 10, 2024

Wired focuses on GLP-1 patient fallout

Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.

October 9, 2024

Quartz mentions APC

Not a big deal, but it shows we're getting media coverage across the spectrum.

October 9, 2024

San Diego news radio focuses on GLP-1 price

It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻

October 9, 2024

CNN gets it spot on

The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.

October 9, 2024

Medscape focuses on compounders

Medscape is the latest news outlet to cover tirzepatide, and it focuses on APC's perspective.

October 7, 2024

Commenting on the tirzepatide announcement

Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective.

October 4, 2024

Talking about those legal threats

Baseless but time-consuming lawsuit threats make compounders shy.

September 27, 2024

APC does its best in a Hill article

The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott.

September 27, 2024

Weighing in on Lilly’s tirzepatide vials

Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly.

September 27, 2024

Shortage compounding is not a loophole, Scott explains to Axios

"It is absolutely intentional policy on the part of FDA."

September 27, 2024

Scott predicts ongoing off-and-on shortages

Don't expect brand-name GLP1s to be available long-term, he says

September 25, 2024

Tenille talks about the cost of firefighters’ lives

The California Board of Pharmacy looked to ban glutathione, but the pushback was hard.

September 24, 2024

Older Entries »